Unicycive Therapeutics Inc (UNCY) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.83 (+1.26%), Market cap $0.20B, 52-week low–high $0.53 ~ $8.56.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, Ca
Financial statements, price targets, institutional (13F) holdings and related news for Unicycive Therapeutics Inc are updated in real time on BlackAll Trade.
Unicycive Therapeutics Inc trades at $4.83 (+1.26%). Real-time quotes and charts are available on BlackAll Trade.
Unicycive Therapeutics Inc has a market cap of about $0.20B.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanth